Decitabine, differently from DNMT1 silencing, exerts its antiproliferative activity through p21 upregulation in malignant pleural mesothelioma (MPM) cells

Abstract

a b s t r a c tMalignant pleural mesothelioma (MPM) is a locally aggressive neoplasm, principally linked to asbestos fibres exposure. Strong evidences associate this pollutant with induction of DNA breaks, aberrant chromosomes segregation and important chromosomal rearrangements, considered crucial events in malignant transformation. A considerable contribution to cellular transformation in MPM is also given by the presence of high genomic instability, as well as by the increased DNA methylation, and consequent decreased expression, of tumor-suppressor genes. In this study we first demonstrated that MPM cells are characterized by a decreased methylation level of pericentromeric DNA sequences which can justify, at least in part, the genomic instability observed in this neoplasia. Concomitantly, we found a paradoxical increased expression of DNMT1, the most expressed DNA methyltransferases in MPM cells, DNMT3a and all five isoforms of DNMT3b. Thus, we compared two experimental strategies, DNMT1 silencing and usage of a demethylating agent (5-aza-2 -deoxycytidine or Decitabine), both theoretically able to revert the locally hypermethylated phenotype and considered potential future therapeutic approaches for MPM. Interestingly, both strategies substantially decrease cell survival of MPM cells but the antitumor activity of Decitabine, differently from DNMT1 silencing, is mediated, at least in part, by a p53-independent p21 upregulation, and is characterized by the arrest of MPM cells at the G2/M phase of the cell cycle. These results indicate that the two approaches act probably through different mechanisms and, thus, that DNMT1 silencing can be considered an effective alternative to Decitabine for cancer treatment.

Epigenetic Modulation Enhances the Therapeutic Effect of Anti–IL-13Rα2 Antibody in Human Mesothelioma Xenografts

“…In vitro data and results from a mouse xenograft model support the use of HDACi in the clinical setting, and vorinostat is being evaluated in a phase III multicenter trial (28). The role of DNMTi in malignant mesothelioma has not been investigated in depth (29,30).…”

Effects of Fifty-Hertz Electromagnetic Fields on Granulocytic Differentiation of ATRA-Treated Acute Promyelocytic Leukemia NB4 Cells

“…Immortalised acute promyelocytic leukemia (NB4) human cells were cultured in RPMI 1640 medium (Lonza) supplemented with 10% (v/v) foetal bovine serum (Gibco), 1% penicillin-streptomycin and 1% L-glutamine (Gibco) in a humidified atmosphere at 37°C [31, 32]. …”

Premature senescence induced by DNA demethylating agent (Decitabine) as therapeutic option for malignant pleural mesothelioma

“…It is frequently associated with asbestos exposure and characterized by altered DNA methylation patterns [1,2]. One of the most frequent genetic alterations found in mesothelioma is the homozygous deletion of INK4a/ARF locus (in more than 70% of the cases) that contributes to two tumor suppressor cellular pathways, the ARF/p53 and the INK4a/RB [1].…”